Cargando…
Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy
Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (IRAEs). Characterisation and data on treatment of musculoskeletal IRAEs are scarce. In this cohort study, patients receiving ICI therapy who experienced arthralgia were evaluated for the presence of synovitis. Data on demog...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109812/ https://www.ncbi.nlm.nih.gov/pubmed/30167328 http://dx.doi.org/10.1136/rmdopen-2018-000714 |
_version_ | 1783350384223322112 |
---|---|
author | Leipe, Jan Christ, Lisa A Arnoldi, Andreas P Mille, Erik Berger, Frank Heppt, Markus Goldscheider, Ilana Kauffmann-Guerrero, Diego Huber, Rudolf M Dechant, Claudia Berking, Carola Schulze-Koops, Hendrik Skapenko, Alla |
author_facet | Leipe, Jan Christ, Lisa A Arnoldi, Andreas P Mille, Erik Berger, Frank Heppt, Markus Goldscheider, Ilana Kauffmann-Guerrero, Diego Huber, Rudolf M Dechant, Claudia Berking, Carola Schulze-Koops, Hendrik Skapenko, Alla |
author_sort | Leipe, Jan |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (IRAEs). Characterisation and data on treatment of musculoskeletal IRAEs are scarce. In this cohort study, patients receiving ICI therapy who experienced arthralgia were evaluated for the presence of synovitis. Data on demographics, ICI regime, time of onset, imaging and response to therapy of synovitis were prospectively collected. Arthritis was demonstrated in 14 of 16 patients of whom 7 showed monarthritis, 5 had oligoarthritis and 2 had polyarthritis. Patients with ICI-induced arthritis were predominantly male (57%) and seronegative (69%). Regarding the detection of synovitis in staging imaging, moderate sensitivity for contrast-enhanced CT with PET-CT as reference was observed. Disease burden at baseline was high and was significantly reduced after anti-inflammatory treatment. Nine patients were treated with systemic and eight patients with intra-articular glucocorticoids. Six patients who flared on glucocorticoid treatment on tapering were given methotrexate resulting in long-term remission. Patients with synovitis were more likely to have good tumour response. Patients with ICI-induced arthritis were predominantly male and seronegative showing different patterns of arthritis with high disease burden. Good efficacy and safety was observed for methotrexate, particularly for ICI-induced polyarthritis. |
format | Online Article Text |
id | pubmed-6109812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-61098122018-08-30 Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy Leipe, Jan Christ, Lisa A Arnoldi, Andreas P Mille, Erik Berger, Frank Heppt, Markus Goldscheider, Ilana Kauffmann-Guerrero, Diego Huber, Rudolf M Dechant, Claudia Berking, Carola Schulze-Koops, Hendrik Skapenko, Alla RMD Open Autoimmunity Immune checkpoint inhibitors (ICIs) may cause immune-related adverse events (IRAEs). Characterisation and data on treatment of musculoskeletal IRAEs are scarce. In this cohort study, patients receiving ICI therapy who experienced arthralgia were evaluated for the presence of synovitis. Data on demographics, ICI regime, time of onset, imaging and response to therapy of synovitis were prospectively collected. Arthritis was demonstrated in 14 of 16 patients of whom 7 showed monarthritis, 5 had oligoarthritis and 2 had polyarthritis. Patients with ICI-induced arthritis were predominantly male (57%) and seronegative (69%). Regarding the detection of synovitis in staging imaging, moderate sensitivity for contrast-enhanced CT with PET-CT as reference was observed. Disease burden at baseline was high and was significantly reduced after anti-inflammatory treatment. Nine patients were treated with systemic and eight patients with intra-articular glucocorticoids. Six patients who flared on glucocorticoid treatment on tapering were given methotrexate resulting in long-term remission. Patients with synovitis were more likely to have good tumour response. Patients with ICI-induced arthritis were predominantly male and seronegative showing different patterns of arthritis with high disease burden. Good efficacy and safety was observed for methotrexate, particularly for ICI-induced polyarthritis. BMJ Publishing Group 2018-08-17 /pmc/articles/PMC6109812/ /pubmed/30167328 http://dx.doi.org/10.1136/rmdopen-2018-000714 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Autoimmunity Leipe, Jan Christ, Lisa A Arnoldi, Andreas P Mille, Erik Berger, Frank Heppt, Markus Goldscheider, Ilana Kauffmann-Guerrero, Diego Huber, Rudolf M Dechant, Claudia Berking, Carola Schulze-Koops, Hendrik Skapenko, Alla Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
title | Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
title_full | Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
title_fullStr | Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
title_full_unstemmed | Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
title_short | Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
title_sort | characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy |
topic | Autoimmunity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109812/ https://www.ncbi.nlm.nih.gov/pubmed/30167328 http://dx.doi.org/10.1136/rmdopen-2018-000714 |
work_keys_str_mv | AT leipejan characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT christlisaa characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT arnoldiandreasp characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT milleerik characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT bergerfrank characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT hepptmarkus characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT goldscheiderilana characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT kauffmannguerrerodiego characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT huberrudolfm characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT dechantclaudia characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT berkingcarola characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT schulzekoopshendrik characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy AT skapenkoalla characteristicsandtreatmentofnewonsetarthritisaftercheckpointinhibitortherapy |